Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite type 1 diabetes trialnet data

Diabetes

Volumn 61, Issue 8, 2012, Pages 2066-2073

  Greenbaum, Carla J ^a   Beam, Craig A ^b   Boulware, David ^b   Gitelman, Stephen E ^c   Gottlieb, Peter A ^d   Herold, Kevan C ^e   Lachin, John M ^f   McGee, Paula ^f   Palmer, Jerry P ^g   Pescovitz, Mark D ^h   Krause Steinrauf, Heidi ^f   Skyler, Jay S ⁱ   Sosenko, Jay M ⁱ  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO DENVER   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE;

ADOLESCENT; ADULT; ARTICLE; CELL SURVIVAL; CHILD; CLINICAL RESEARCH; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZATION; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ADULT; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864381301     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1538     Document Type: Article

References (33)

1. Fourlanos S, Varney MD, Tait BD, et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 2008;31:1546-1549
2. Hermann R, Knip M, Veijola R, et al.; FinnDiane Study Group. Temporal changes in the frequencies of HLA genotypes in patients with type 1 diabetes - indication of an increased environmental pressure? Diabetologia 2003;46:420-425 (Pubitemid 36547599)
3. Ogden CL, Carroll M. Prevalence of overweight, obesity, and extreme obesity among adults: United States, trends 1960-1962 through 2007-2008 [article online], 2010. Available from www.cdc.gov/NCHS/data/hestat/obesity-adult-07-08/ obesity-adult-07-08.pdf. Accessed 25 June 2011
4. Ogden CL, Carroll M. Prevalence of obesity among children and adolescents: United States, trends 1963-1965 through 2007-2008 [article online], 2010. Available from www.cdc.gov/nchs/data/hestat/obesity-child-07-08/obesity- child-07-08.pdf. Accessed 25 June 2011
5. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853
6. Atkinson MA, Gianani R. The pancreas in human type 1 diabetes: providing new answers to age-old questions. Curr Opin Endocrinol Diabetes Obes 2009;16:279-285
7. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010;33:826-832
8. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412-419
9. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
10. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
11. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769 (Pubitemid 40770766)
12. Muggeo VM. Estimating regression models with unknown break-points. Stat Med 2003;22:3055-3071 (Pubitemid 37160605)
13. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836 (Pubitemid 36929351)
14. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523
15. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355:1318-1330 (Pubitemid 44465460)
16. Greenbaum CJ, Buckingham B, Chase HP, Krischer J; Diabetes Prevention Trial, Type 1 Diabetes (DPT-1) Study Group.Metabolic tests to determine risk for type 1 diabetes in clinical trials. Diabetes Metab Res Rev 2011;27:584-589
17. Sosenko JM, Palmer JP, Greenbaum CJ, et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643-649 (Pubitemid 44115367)
18. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
19. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691
20. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009;10:97-104
21. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005;28:1068-1076 (Pubitemid 40616615)
22. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698 (Pubitemid 34547482)
23. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608 (Pubitemid 41007846)
24. Petrone A, Galgani A, Spoletini M, et al. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab Res Rev 2005;21:271-275 (Pubitemid 40716159)
25. Greenbaum CJ, Anderson AM, Dolan LM, et al.; SEARCH Study Group. Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 2009;32:1839-1844
26. Palmer JP. C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev 2009;25:325-328
27. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 1995;45:486-490
28. Komulainen J, Knip M, Lounamaa R, et al.; The Childhood Diabetes in Finland Study Group. Poor beta-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. Diabet Med 1997;14:532-537 (Pubitemid 27298812)
29. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J. Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 1992;15:66-74
30. Törn C, Landin-Olsson M, Lernmark A, et al. Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000;85:4619-4623 (Pubitemid 32157642)
31. Chase HP, Cuthbertson DD, Dolan LM, et al. First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes. J Pediatr 2001;138:244-249 (Pubitemid 32156441)
32. Karasuyama H, Mukai K, Obata K, Tsujimura Y, Wada T. Nonredundant roles of basophils in immunity. Annu Rev Immunol 2011;29:45-69
33. Wherrett DK, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011;378:319-327